Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma

Jonathan Zagzag, Aron Pollack, Linda Dultz, Shumon Dhar, Jennifer B. Ogilvie, Keith S. Heller, Fang Ming Deng, Kepal N. Patel

Research output: Contribution to journalArticle

Abstract

Background BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). We used a mutation-specific antibody for immunohistochemical (IHC) detection of the BRAF V600E mutation and correlated expression with clinicopathologic features. The study was designed to validate the accuracy and determine the clinical importance of IHC detection of the BRAF V600E mutation in PTC. Methods Direct sequencing and IHC for BRAF V600E mutation was performed in 37 consecutive patients with PTCs. IHC was scored on an intensity proportion scale. IHC positive tumors were stratified into intensity categories. The categories were assessed for clinicopathologic variables, including age, extrathyroidal extension, lymphovascular invasion, and lymph node metastases. Results A total of 25 PTCs were BRAF V600E-positive and 12 were BRAF mutation-negative on IHC. The BRAF V600E mutation-specific antibody had a sensitivity of 89% and specificity of 100% for detecting the mutation. Tumors with high-intensity staining were more likely to have extrathyroidal extension. Conclusion IHC is an accurate method for the detection of the BRAF V600E mutation in PTC, and its ability to quantify the mutation expression may serve as a better predictor of tumor behavior than molecular sequencing. It provides a potentially rapid, easily applicable, and economic alternative to current techniques.

Original languageEnglish (US)
Pages (from-to)1199-1205
Number of pages7
JournalSurgery (United States)
Volume154
Issue number6
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Immunohistochemistry
Mutation
Factor IX
Papillary Thyroid cancer
Neoplasms
Antibodies
Lymph Nodes
Economics
Staining and Labeling
Neoplasm Metastasis
Sensitivity and Specificity

ASJC Scopus subject areas

  • Surgery

Cite this

Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. / Zagzag, Jonathan; Pollack, Aron; Dultz, Linda; Dhar, Shumon; Ogilvie, Jennifer B.; Heller, Keith S.; Deng, Fang Ming; Patel, Kepal N.

In: Surgery (United States), Vol. 154, No. 6, 12.2013, p. 1199-1205.

Research output: Contribution to journalArticle

Zagzag, Jonathan ; Pollack, Aron ; Dultz, Linda ; Dhar, Shumon ; Ogilvie, Jennifer B. ; Heller, Keith S. ; Deng, Fang Ming ; Patel, Kepal N. / Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. In: Surgery (United States). 2013 ; Vol. 154, No. 6. pp. 1199-1205.
@article{fae73104b0634091816c21bf1a505958,
title = "Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma",
abstract = "Background BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). We used a mutation-specific antibody for immunohistochemical (IHC) detection of the BRAF V600E mutation and correlated expression with clinicopathologic features. The study was designed to validate the accuracy and determine the clinical importance of IHC detection of the BRAF V600E mutation in PTC. Methods Direct sequencing and IHC for BRAF V600E mutation was performed in 37 consecutive patients with PTCs. IHC was scored on an intensity proportion scale. IHC positive tumors were stratified into intensity categories. The categories were assessed for clinicopathologic variables, including age, extrathyroidal extension, lymphovascular invasion, and lymph node metastases. Results A total of 25 PTCs were BRAF V600E-positive and 12 were BRAF mutation-negative on IHC. The BRAF V600E mutation-specific antibody had a sensitivity of 89{\%} and specificity of 100{\%} for detecting the mutation. Tumors with high-intensity staining were more likely to have extrathyroidal extension. Conclusion IHC is an accurate method for the detection of the BRAF V600E mutation in PTC, and its ability to quantify the mutation expression may serve as a better predictor of tumor behavior than molecular sequencing. It provides a potentially rapid, easily applicable, and economic alternative to current techniques.",
author = "Jonathan Zagzag and Aron Pollack and Linda Dultz and Shumon Dhar and Ogilvie, {Jennifer B.} and Heller, {Keith S.} and Deng, {Fang Ming} and Patel, {Kepal N.}",
year = "2013",
month = "12",
doi = "10.1016/j.surg.2013.06.020",
language = "English (US)",
volume = "154",
pages = "1199--1205",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma

AU - Zagzag, Jonathan

AU - Pollack, Aron

AU - Dultz, Linda

AU - Dhar, Shumon

AU - Ogilvie, Jennifer B.

AU - Heller, Keith S.

AU - Deng, Fang Ming

AU - Patel, Kepal N.

PY - 2013/12

Y1 - 2013/12

N2 - Background BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). We used a mutation-specific antibody for immunohistochemical (IHC) detection of the BRAF V600E mutation and correlated expression with clinicopathologic features. The study was designed to validate the accuracy and determine the clinical importance of IHC detection of the BRAF V600E mutation in PTC. Methods Direct sequencing and IHC for BRAF V600E mutation was performed in 37 consecutive patients with PTCs. IHC was scored on an intensity proportion scale. IHC positive tumors were stratified into intensity categories. The categories were assessed for clinicopathologic variables, including age, extrathyroidal extension, lymphovascular invasion, and lymph node metastases. Results A total of 25 PTCs were BRAF V600E-positive and 12 were BRAF mutation-negative on IHC. The BRAF V600E mutation-specific antibody had a sensitivity of 89% and specificity of 100% for detecting the mutation. Tumors with high-intensity staining were more likely to have extrathyroidal extension. Conclusion IHC is an accurate method for the detection of the BRAF V600E mutation in PTC, and its ability to quantify the mutation expression may serve as a better predictor of tumor behavior than molecular sequencing. It provides a potentially rapid, easily applicable, and economic alternative to current techniques.

AB - Background BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). We used a mutation-specific antibody for immunohistochemical (IHC) detection of the BRAF V600E mutation and correlated expression with clinicopathologic features. The study was designed to validate the accuracy and determine the clinical importance of IHC detection of the BRAF V600E mutation in PTC. Methods Direct sequencing and IHC for BRAF V600E mutation was performed in 37 consecutive patients with PTCs. IHC was scored on an intensity proportion scale. IHC positive tumors were stratified into intensity categories. The categories were assessed for clinicopathologic variables, including age, extrathyroidal extension, lymphovascular invasion, and lymph node metastases. Results A total of 25 PTCs were BRAF V600E-positive and 12 were BRAF mutation-negative on IHC. The BRAF V600E mutation-specific antibody had a sensitivity of 89% and specificity of 100% for detecting the mutation. Tumors with high-intensity staining were more likely to have extrathyroidal extension. Conclusion IHC is an accurate method for the detection of the BRAF V600E mutation in PTC, and its ability to quantify the mutation expression may serve as a better predictor of tumor behavior than molecular sequencing. It provides a potentially rapid, easily applicable, and economic alternative to current techniques.

UR - http://www.scopus.com/inward/record.url?scp=84887995180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887995180&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2013.06.020

DO - 10.1016/j.surg.2013.06.020

M3 - Article

C2 - 23931769

AN - SCOPUS:84887995180

VL - 154

SP - 1199

EP - 1205

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 6

ER -